<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314000</url>
  </required_header>
  <id_info>
    <org_study_id>A4046</org_study_id>
    <secondary_id>90987574</secondary_id>
    <nct_id>NCT02314000</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude</brief_title>
  <acronym>WHISPER</acronym>
  <official_title>WHISPER - A Randomized Controlled Study to Evaluate the Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate sustained clinically significant pain relief in patients with chronic pain
      when using the Boston Scientific Precision Spinal Cord Stimulator (SCS) System at
      sub‐perception amplitude
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate sustained clinically significant pain relief in patients when using the Boston
      Scientific Precision Spinal Cord Stimulator (SCS) System at sub‐perception amplitude
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With 50% or Greater Reduction in Overall Pain Intensity From Baseline</measure>
    <time_frame>90 days post activation</time_frame>
    <description>Proportion of subjects with 50% or greater reduction in overall pain intensity from baseline with supra and sub perception amplitude with no increase in average daily medication intake to treat pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>SCS starting with supra-perception</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCS starting with sub-perception amplitude</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Precision or Precision Spectra Spinal Cord Stimulator System</intervention_name>
    <arm_group_label>SCS starting with sub-perception amplitude</arm_group_label>
    <arm_group_label>SCS starting with supra-perception</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Complaint of chronic pain of the trunk and/or limbs

          2. Willing and able to comply with all protocol-required procedures and
             assessments/evaluations; able to independently read and complete all questionnaires
             and assessments provided in English

          3. Subject signed a valid, Institutional Review Board (IRB)-approved informed consent
             form (ICF) provided in English

        Key Exclusion Criteria:

          1. Meets any contraindication in the Precision SCS system per locally applicable
             Directions for Use (DFU)

          2. Any pain-related diagnosis or medical/psychological condition that, in the clinician's
             best judgment, might confound reporting of study outcomes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roshini Jain, M.S.</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Neuromodulation Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Scientific Clinical Research Information Toll Free Number</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2014</study_first_posted>
  <results_first_submitted>February 16, 2018</results_first_submitted>
  <results_first_submitted_qc>March 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2019</results_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrolled subjects underwent study eligibility to determine if they can continue in the study. Following completion of study eligibility, subjects were randomized to the cross-over phase.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SCS Starting With Supra-perception Amplitude</title>
          <description>Precision or Precision Spectra Spinal Cord Stimulator System programmed starting with supra-perception followed by sub‐perception amplitude.
Precision or Precision Spectra Spinal Cord Stimulator System</description>
        </group>
        <group group_id="P2">
          <title>SCS Starting With Sub-perception Amplitude</title>
          <description>Precision or Precision Spectra Spinal Cord Stimulator System programmed starting with sub-perception and followed by supra‐perception amplitude.
Precision or Precision Spectra Spinal Cord Stimulator System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SCS Starting at Supra-perception Amplitude</title>
          <description>Precision or Precision Spectra Spinal Cord Stimulator System programmed starting at supra-perception and followed by sub‐perception amplitude.
Precision or Precision Spectra Spinal Cord Stimulator System</description>
        </group>
        <group group_id="B2">
          <title>SCS Starting at Sub-perception Amplitude</title>
          <description>Precision or Precision Spectra Spinal Cord Stimulator System starting at sub-perception and followed by supra‐perception amplitude.
Precision or Precision Spectra Spinal Cord Stimulator System</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="11.9"/>
                    <measurement group_id="B2" value="58.8" spread="10.7"/>
                    <measurement group_id="B3" value="59.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With 50% or Greater Reduction in Overall Pain Intensity From Baseline</title>
        <description>Proportion of subjects with 50% or greater reduction in overall pain intensity from baseline with supra and sub perception amplitude with no increase in average daily medication intake to treat pain</description>
        <time_frame>90 days post activation</time_frame>
        <population>Due to the nature of crossover study design, all subjects contributed towards each arm, as reflected in the number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SCS With Supra-perception Amplitude</title>
            <description>Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception amplitude
Precision or Precision Spectra Spinal Cord Stimulator System</description>
          </group>
          <group group_id="O2">
            <title>SCS With Sub-perception Amplitude</title>
            <description>Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception amplitude
Precision or Precision Spectra Spinal Cord Stimulator System</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With 50% or Greater Reduction in Overall Pain Intensity From Baseline</title>
          <description>Proportion of subjects with 50% or greater reduction in overall pain intensity from baseline with supra and sub perception amplitude with no increase in average daily medication intake to treat pain</description>
          <population>Due to the nature of crossover study design, all subjects contributed towards each arm, as reflected in the number of participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events up to end of cross over period - approximately upto 180 days after randomization</time_frame>
      <desc>Adverse events up to end of cross over period - approximately upto 180 days after randomization</desc>
      <group_list>
        <group group_id="E1">
          <title>All Study Patients Through End of Randomized Phase</title>
          <description>All adverse events reported through end of randomized phase</description>
        </group>
        <group group_id="E2">
          <title>SCS With Supra Perception Amplitude</title>
          <description>All adverse events during SCS with supra perception amplitude</description>
        </group>
        <group group_id="E3">
          <title>SCS With Subperception Amplitude</title>
          <description>All adverse events during SCS with supra perception amplitude</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDrRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Enterocolitis Heamorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Post Procedure Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Clinical study agreement that restricts PI until official study manuscript is available.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roshini Jain, Director of Clinical Sciences</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>6619494355</phone>
      <email>roshini.jain@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

